利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

95 条记录 (耗时 0.029 秒)

    CHIMERIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE
    1.
    发明申请
    CHIMERIC T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE 审中-公开
    CHIMERIC T细胞受体及相关材料及使用方法

    公开(公告)号：US20090304657A1

    公开(公告)日：2009-12-10

    申请号：US12298927

    申请日：2007-05-03

    申请人： Richard A. Morgan ,  Cyrille J. Cohen ,  Steven A. Rosenberg

    发明人： Richard A. Morgan ,  Cyrille J. Cohen ,  Steven A. Rosenberg

    IPC分类号： A61K35/12 ,  C12N5/08 ,  C07K14/705 ,  C07H21/04 ,  C12N15/63 ,  C12N5/00

    CPC分类号： C07K14/7051 ,  C07K2319/00 ,  G01N33/6893

    摘要： The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR.

    摘要翻译： 本发明提供了包含人TCR的可变区和包含非人TCR的恒定区的至少胞外结构域的恒定区的嵌合T细胞受体（TCR）及其功能变体。 本发明还提供与本发明的TCR相关的多肽和蛋白质，以及编码TCR，多肽或蛋白质，重组表达载体和宿主细胞的核酸。 进一步提供的是与本发明的TCR相关的药物组合物和预防或治疗疾病例如感染性疾病，宿主中的癌症，检测宿主中的病变细胞的方法的方法以及改善宿主的生物活性的方法 TCR。

    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS
    4.
    发明申请
    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 有权
    改良的T细胞受体及相关材料与方法

    公开(公告)号：US20100034834A1

    公开(公告)日：2010-02-11

    申请号：US12443111

    申请日：2007-09-26

    申请人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    发明人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    IPC分类号： A61K39/395 ,  C07K16/30 ,  C12N15/11 ,  C12N15/00 ,  C12N5/10 ,  G01N33/53 ,  G01N33/574 ,  C12Q1/68

    CPC分类号： G01N33/505 ,  A61K38/00 ,  C07K14/7051 ,  G01N33/5091

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.

    摘要翻译： 本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

    Modified T cell receptors and related materials and methods
    5.
    发明授权
    Modified T cell receptors and related materials and methods 有权
    改良T细胞受体及相关材料及方法

    公开(公告)号：US09128080B2

    公开(公告)日：2015-09-08

    申请号：US13304841

    申请日：2011-11-28

    申请人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg

    发明人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg

    IPC分类号： C07H21/04 ,  G01N33/50 ,  C07K14/725 ,  A61K38/00

    CPC分类号： G01N33/505 ,  A61K38/00 ,  C07K14/7051 ,  G01N33/5091

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.

    摘要翻译： 本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

    INDUCIBLE INTERLEUKIN-12
    7.
    发明申请
    INDUCIBLE INTERLEUKIN-12 有权
    可诱导的白细胞介素12

    公开(公告)号：US20120071859A1

    公开(公告)日：2012-03-22

    申请号：US13266280

    申请日：2010-04-22

    申请人： Richard A. Morgan ,  Steven A. Rosenberg ,  Ling Zhang ,  Nicholas P. Restifo

    发明人： Richard A. Morgan ,  Steven A. Rosenberg ,  Ling Zhang ,  Nicholas P. Restifo

    IPC分类号： A61M37/00 ,  A61K31/711 ,  A61P35/00 ,  C12N1/11 ,  C12N5/10 ,  C12N1/15 ,  C12N1/13 ,  C12N1/21 ,  C12N15/24 ,  A61P31/00

    CPC分类号： C07K14/5434 ,  A61K38/00 ,  C07K14/4702 ,  Y02A50/411

    摘要： The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3′ of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.

    摘要翻译： 本发明提供了分离或纯化的核酸，其包含编码与编码IL-12的核苷酸序列可操作地相关的活化T细胞（NFAT）启动子核因子的核苷酸序列。 本发明还提供了一种核酸，其包含编码与编码IL-12的核苷酸序列可操作地相关的活化的T细胞（NFAT）启动子的核因子的核苷酸序列，其中所述NFAT启动子位于编码IL-12的核苷酸序列的3' 12。 还提供了相关的重组表达载体，宿主细胞，细胞群和药物组合物。 本发明进一步提供了本发明的核酸或相关材料在哺乳动物中治疗或预防癌症或感染性疾病以及在哺乳动物中诱导IL-12表达的用途。

    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS
    8.
    发明申请
    MODIFIED T CELL RECEPTORS AND RELATED MATERIALS AND METHODS 有权
    改良的T细胞受体及相关材料与方法

    公开(公告)号：US20120071420A1

    公开(公告)日：2012-03-22

    申请号：US13304841

    申请日：2011-11-28

    申请人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    发明人： Paul F. Robbins ,  Richard A. Morgan ,  Steven A. Rosenberg ,  Alan David Bennett

    IPC分类号： A61K38/02 ,  A61P31/00 ,  C12Q1/02 ,  A61P35/00

    CPC分类号： G01N33/505 ,  A61K38/00 ,  C07K14/7051 ,  G01N33/5091

    摘要： The invention is directed to a modified T cell receptor (TCR) comprising an amino acid sequence of a wild-type (WT) TCR with no more than three amino acid substitutions, wherein the modified TCR, as compared to the WT TCR, (i) has an enhanced ability to recognize target cells when expressed by CD4+ T cells and (ii) does not exhibit a decrease in antigen specificity when expressed by CD8+ T cells. Polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions related to the modified TCR also are part of the invention. Further, the invention is directed to methods of detecting a diseased cell in a host, methods of treating or preventing a disease in a host, and methods of identifying a candidate adoptive immunotherapy TCR.

    摘要翻译： 本发明涉及包含不超过三个氨基酸取代的野生型（WT）TCR的氨基酸序列的修饰的T细胞受体（TCR），其中与WT TCR相比，修饰的TCR（i ）当由CD4 + T细胞表达时具有增强的识别靶细胞的能力，和（ii）当由CD8 + T细胞表达时不显示抗原特异性的降低。 多肽，蛋白质，核酸，重组表达载体，宿主细胞，细胞群，抗体和与修饰的TCR相关的药物组合物也是本发明的一部分。 此外，本发明涉及检测宿主中的病变细胞的方法，治疗或预防宿主疾病的方法，以及鉴定候选的过继性免疫治疗TCR的方法。

    Inducible interleukin-12
    10.
    发明授权
    Inducible interleukin-12 有权
    诱导性白细胞介素-12

    公开(公告)号：US08556882B2

    公开(公告)日：2013-10-15

    申请号：US13266280

    申请日：2010-04-22

    申请人： Richard A. Morgan ,  Steven A. Rosenberg ,  Ling Zhang ,  Nicholas P. Restifo

    发明人： Richard A. Morgan ,  Steven A. Rosenberg ,  Ling Zhang ,  Nicholas P. Restifo

    IPC分类号： C12N1/15 ,  C12N1/13 ,  C12N1/21

    CPC分类号： C07K14/5434 ,  A61K38/00 ,  C07K14/4702 ,  Y02A50/411

    摘要： The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3′ of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.

    摘要翻译： 本发明提供了分离或纯化的核酸，其包含编码与编码IL-12的核苷酸序列可操作地相关的活化T细胞（NFAT）启动子核因子的核苷酸序列。 本发明还提供了一种核酸，其包含编码与编码IL-12的核苷酸序列可操作地相关的活化的T细胞（NFAT）启动子的核因子的核苷酸序列，其中所述NFAT启动子位于编码IL-12的核苷酸序列的3' 12。 还提供了相关的重组表达载体，宿主细胞，细胞群和药物组合物。 本发明进一步提供了本发明的核酸或相关材料在哺乳动物中治疗或预防癌症或感染性疾病以及在哺乳动物中诱导IL-12表达的用途。